New Combination Treatment for Recurrent Ovarian Cancer Shows Positive Outcomes

November 19, 2020 5:00 pm

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

In a new article in JAMA Oncology, the … Read more

‘Next-Gen’ Immunotherapy Active in Advanced Cancers

November 16, 2020 5:00 pm

Disease control in two-thirds of patients treated with bispecific antibody.

By Charles Bankhead

An investigational drug that combines PD-1/L1 inhibition and T-cell stimulation led to disease control in two-thirds of patients with unresectable advanced solid malignancies, a preliminary clinical study … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

A Common Plant Virus Is an Unlikely Ally in the War on Cancer

October 5, 2020 3:00 pm

Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.

By Daniel Oberhaus

Jack Hoopes spends a lot of time with dying dogs. A veterinary radiation specialist
Read more

Immunotherapy Falls Short Again in Ovarian Cancer

September 23, 2020 6:00 pm

No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.

By Charles Bankhead

An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more

STING Activation Touted as Potential Immunotherapy for Cancer

August 25, 2020 9:00 am

A Scripps Research team reports the discovery of a molecule that can activate a natural immune-boosting protein called STING. The findings mark a key advance in the field of oncology, as the STING protein is known for its strong antitumor … Read more

Chemotherapy, Surgery for Gynecologic Cancer Not Linked to Higher COVID-19 Mortality Risk

July 30, 2020 3:00 pm

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

However, recent immunotherapy use … Read more

Study: The Immune Effects of Seclidemstat in Aggressive Ovarian Cancer Striking Young Women

July 13, 2020 3:00 pm

A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

Published today in the scientific … Read more

New Cancer Vaccine Ready for Human Trials

July 10, 2020 6:00 pm

According to new research published in Clinical and Translational Immunology, a new cancer vaccine is ready for human trials following its success in preclinical studies.

By Alana Hippensteele

The vaccine was recently developed by a research team based at The … Read more

This MicroRNA Might Help Detect, Treat Ovarian Cancer

June 26, 2020 6:00 pm

In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

By Ian Demsky

A microRNA that is normally involved in immune cell differentiation helps to initiate

Read more

FDA Approves Pembrolizumab for TMB-High Tumors

June 16, 2020 3:00 am

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.Read more

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

June 3, 2020 5:00 pm

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).

In the interim … Read more

Abclon Derives Clinical Materials for CAR-T Treatment of Ovarian Cancer

April 21, 2020 6:00 pm

By Shim Hyun-tai

Antibody-based therapeutics developer Abclon said Tuesday that it has successfully drawn final candidates for the clinical trials of the next-generation chimeric antigen receptor T (CAR-T) cell therapy for ovarian cancer.

Abclon plans to enter clinical trials in … Read more

New Cancer Drug Shrinks Tumors, Reduces Side Effects, in Animal Studies

April 15, 2020 10:00 am

By Brita Belli

A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more

Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer

April 2, 2020 10:30 am

By Gina Columbus

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more

New Type of Immunotherapy Hinders the Spread of Ovarian Cancer

March 26, 2020 10:00 am

Malignant ovarian cancer is insidious: Known and feared for vague and uncharacteristic symptoms that often mean the disease is discovered so late that on average only four out of six patients are still alive after five years. Researchers from Aarhus … Read more

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 26, 2020 10:00 am

By Jason M. Broderick

An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more

Immunotherapy With Neoadjuvant Chemotherapy Signals Efficacy in Advanced-Stage Ovarian Cancer

March 19, 2020 11:00 am

By Nichole Tucker

GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more

IMV preps pivotal trials for ovarian cancer T cell therapy

February 26, 2020 11:00 am

IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.

The Canadian biotech revealed data from the 22-patient … Read more

IFN-Activated Monocytes Show Early Promise For Ovarian Cancer

February 13, 2020 11:00 am

By Sharon Worcester

REPORTING FROM THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

– Intraperitoneal infusions of peginterferon alfa-2b and interferon gamma-1b, administered with or without autologous monocytes, showed antitumor activity and tolerability in heavily pretreated patients with ovarian cancer in a first-in-human
Read more